Abstract: A vehicle door frame structure has an upper sash member located along a roof panel of a vehicle body and also has a vertical pillar sash member located along a center pillar of the vehicle body. The upper sash member has, at its linear end joined to the vertical pillar sash member side, an aesthetically designed section and an inner frame portion. The aesthetically designed section is located on the outer side of the door, and the inner frame portion is located closer to the vehicle interior than the aesthetically designed section and is shorter in length than the aesthetically designed section. The vertical pillar sash member has at its upper end a superposed contact section that is superposed, in the direction of the thickness of the door, on an end of the inner frame portion of the upper sash member, and the superposed contact section and the inner frame portion are joined together while being superposed on each other.

Abstract: A vehicle door frame structure has an upper sash member located along a roof panel of a vehicle body and also has a vertical pillar sash member located along a center pillar of the vehicle body. The upper sash member has, at its linear end joined to the vertical pillar sash member side, an aesthetically designed section and an inner frame portion. The aesthetically designed section is located on the outer side of the door, and the inner frame portion is located closer to the vehicle interior than the aesthetically designed section and is shorter in length than the aesthetically designed section. The vertical pillar sash member has at its upper end a superposed contact section that is superposed, in the direction of the thickness of the door, on an end of the inner frame portion of the upper sash member, and the superposed contact section and the inner frame portion are joined together while being superposed on each other.

Abstract: The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.

Abstract: A biphenyl derivative represented by the following general formula (1) and a pharmaceutically acceptable salt thereof: [In the formula (1), A represents a single bond, —CH2—, —CO—, —CS— or —SO2—; B represents a single bond or —CH2—; R1 represents a hydrogen atom, —OH, —NR11R12 (wherein R11 and R12 each independently represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms), —OCOCH3, or a halogen atom; R2 represents a hydrogen atom or R1 and R2 form a group ═O together; R3 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; provided that in the formula, the absolute configuration of the position a may be either R or S]. The compound of the present invention has considerably high safety and efficacy and is useful as, in particular, a vasopressin receptor antagonist.